The document provides an analysis of Fresenius, highlighting a strong outlook with expected defensive low-teens EPS growth to 2020. It discusses weak sentiment due to concerns over IV generics pricing and Akorn's performance, but anticipates strong 4Q17 results. The valuation is considered undemanding, and several positive catalysts are expected. Historical PE values from 1998 to 2017 are provided in a table.
doj/DataSet10/EFTA01385516.pdf
{"title":"Deutsche Bank Research European Equity Focus","key_people":["Gunnar Romer"],"document_date":"January 2018","document_type":"tabular","document_subtype":"financial analysis","key_organizations":["Deutsche Bank","Fresenius","Qirónsalud","Kabi","Akorn"],"reference_numbers":["DB-SDNY-0086802","SDNY_GM_00232986","EFTA01385516"]}